Literature DB >> 3493842

Characterization of the epidermal growth factor receptor in human meningioma.

A S Weisman, S S Raguet, P A Kelly.   

Abstract

We have characterized the epidermal growth factor (EGF) receptor in human meningioma (biopsy) microsomes, cellularly derived microsomes, and intact meningioma cells in culture. Scatchard analysis of competition studies reveals both high and low affinity EGF binding sites in the meningiomas tested [dissociation constant (Kd) = 0.9 nM, maximum number of binding sites (Bmax) = 280 fmol/mg protein; Kd = 5.0 nM, Bmax = 660 fmol/mg protein, respectively]. The binding of 125I-EGF is specific since it is abolished by excess unlabeled EGF but not by excess unlabeled platelet-derived growth factor or insulin. Meningioma cultures preincubated with platelet-derived growth factor (10 ng/ml) at 37 degrees C shifted the 125I-EGF competition curve to the right but did not affect receptor number (100,000 sites/cell) when compared to cultures preincubated at 4 degrees C. Cross-linking studies performed with ethyleneglycol bis(succinimidyl succinate) followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography reveal a major band of specifically bound EGF (Mr approximately 150,000), although the normal (Mr approximately 170,000) and another putative proteolytic form (Mr approximately 125,000) can also be seen. These results indicate that human meningiomas contain a mixed population of EGF binding sites and exhibit properties of previously described EGF receptors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493842

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma.

Authors:  A Gabriella Wernicke; Adam P Dicker; Michal Whiton; Jana Ivanidze; Terry Hyslop; Elizabeth H Hammond; Arie Perry; David W Andrews; Lawrence Kenyon
Journal:  Radiat Oncol       Date:  2010-05-30       Impact factor: 3.481

Review 2.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

Review 3.  Advances in meningioma genetics: novel therapeutic opportunities.

Authors:  Matthias Preusser; Priscilla K Brastianos; Christian Mawrin
Journal:  Nat Rev Neurol       Date:  2018-01-05       Impact factor: 42.937

4.  Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

Authors:  Andrew D Norden; Jeffrey J Raizer; Lauren E Abrey; Kathleen R Lamborn; Andrew B Lassman; Susan M Chang; W K Alfred Yung; Mark R Gilbert; Howard A Fine; Minesh Mehta; Lisa M Deangelis; Timothy F Cloughesy; H Ian Robins; Kenneth Aldape; Janet Dancey; Michael D Prados; Frank Lieberman; Patrick Y Wen
Journal:  J Neurooncol       Date:  2009-06-28       Impact factor: 4.130

5.  Expression of endothelin 1 and its angiogenic role in meningiomas.

Authors:  Laura Boldrini; Sabina Pistolesi; Silvia Gisfredi; Silvia Ursino; Greta Alì; Nicola Pieracci; Fulvio Basolo; Giuliano Parenti; Gabriella Fontanini
Journal:  Virchows Arch       Date:  2006-09-30       Impact factor: 4.064

Review 6.  VEGF in brain tumors.

Authors:  M R Machein; K H Plate
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

7.  Expression of the c-erbB-2-encoded oncoprotein and progesterone receptor in human meningiomas.

Authors:  J Schlegel; B Ullrich; G Stumm; P Gass; I M Harwerth; N E Hynes; M Kiessling
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

8.  Expression of PDGF, PDGF-receptor, EGF-receptor and sex hormone receptors on meningioma.

Authors:  J I Kuratsu; H Seto; M Kochi; Y Ushio
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

9.  Epidermal growth factor receptor and lipid membrane components in human lung cancers.

Authors:  A Di Carlo; A Mariano; P E Macchia; C Cecere; G Ferrante; V Macchia
Journal:  J Endocrinol Invest       Date:  1993-02       Impact factor: 4.256

Review 10.  Medical management of meningiomas.

Authors:  Wendy J Sherman; Jeff J Raizer
Journal:  CNS Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.